Gerber Kawasaki Wealth & Investment Management Has $1.81 Million Position in Stryker Corporation $SYK

Key Points

• Gerber Kawasaki Wealth & Investment Management increased its holdings in Stryker Corporation by 18.9%, acquiring an additional 772 shares, bringing its total to 4,864 shares valued at approximately $1.81 million.
• Stryker's stock has been positively reviewed by multiple analysts, with a consensus rating of "Moderate Buy" and a price target of $430.10, reflecting strong expected performance.
• The company reported earnings of $3.13 per share for its last quarter, exceeding analyst estimates, alongside an increase in revenue of 11.1% from the previous year, reaching $6.02 billion.

Gerber Kawasaki Wealth & Investment Management raised its stake in shares of Stryker Corporation (NYSE:SYK - Free Report) by 18.9% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 4,864 shares of the medical technology company's stock after acquiring an additional 772 shares during the quarter. Gerber Kawasaki Wealth & Investment Management's holdings in Stryker were worth $1,811,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Capital A Wealth Management LLC bought a new position in shares of Stryker during the fourth quarter valued at $26,000. Goodman Advisory Group LLC bought a new position in shares of Stryker during the first quarter valued at $32,000. City Holding Co. lifted its holdings in shares of Stryker by 528.6% during the first quarter. City Holding Co. now owns 88 shares of the medical technology company's stock valued at $33,000 after acquiring an additional 74 shares during the period. Smallwood Wealth Investment Management LLC bought a new position in shares of Stryker during the first quarter valued at $40,000. Finally, Itau Unibanco Holding S.A. bought a new position in shares of Stryker during the fourth quarter valued at $42,000. 77.09% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. JMP Securities reissued a "market perform" rating on shares of Stryker in a report on Monday, May 5th. Truist Financial set a $415.00 price target on Stryker and gave the company a "hold" rating in a report on Monday, August 4th. Sanford C. Bernstein set a $450.00 price target on Stryker in a report on Monday, May 5th. Wells Fargo & Company lifted their price target on Stryker from $435.00 to $445.00 and gave the company an "overweight" rating in a report on Friday, August 1st. Finally, Wall Street Zen raised Stryker from a "hold" rating to a "buy" rating in a report on Friday, July 18th. Fifteen equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $430.10.

Insider Activity

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of the business's stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the completion of the sale, the director directly owned 3,222,108 shares of the company's stock, valued at approximately $1,212,962,556.60. The trade was a 5.84% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Viju Menon sold 500 shares of the business's stock in a transaction dated Monday, August 25th. The stock was sold at an average price of $390.61, for a total value of $195,305.00. Following the transaction, the insider owned 12,511 shares of the company's stock, valued at $4,886,921.71. The trade was a 3.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 5.90% of the company's stock.

Stryker Trading Up 0.5%

NYSE:SYK traded up $1.81 on Friday, hitting $391.48. 672,496 shares of the stock were exchanged, compared to its average volume of 1,266,991. The stock has a market capitalization of $149.67 billion, a price-to-earnings ratio of 51.85, a P/E/G ratio of 2.85 and a beta of 0.91. Stryker Corporation has a 52 week low of $329.16 and a 52 week high of $406.19. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78. The company's 50-day moving average price is $389.26 and its 200 day moving average price is $379.39.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, topping the consensus estimate of $3.07 by $0.06. The firm had revenue of $6.02 billion during the quarter, compared to analysts' expectations of $5.92 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The company's quarterly revenue was up 11.1% compared to the same quarter last year. During the same period in the previous year, the business posted $2.81 EPS. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. On average, equities research analysts forecast that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be issued a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend is Tuesday, September 30th. Stryker's payout ratio is currently 44.50%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.